Fortrea (FTRE) Competitors $5.22 +0.02 (+0.29%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FTRE vs. WGS, LFST, ARDT, PGNY, NHC, GRAL, TDOC, VRDN, AHCO, and CDNAShould you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include GeneDx (WGS), LifeStance Health Group (LFST), Ardent Health (ARDT), Progyny (PGNY), National HealthCare (NHC), GRAIL (GRAL), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), AdaptHealth (AHCO), and CareDx (CDNA). These companies are all part of the "healthcare" industry. Fortrea vs. Its Competitors GeneDx LifeStance Health Group Ardent Health Progyny National HealthCare GRAIL Teladoc Health Viridian Therapeutics AdaptHealth CareDx Fortrea (NASDAQ:FTRE) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has better valuation and earnings, FTRE or WGS? GeneDx has lower revenue, but higher earnings than Fortrea. GeneDx is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortrea$2.70B0.18-$328.50M-$8.79-0.59GeneDx$305.45M8.35-$52.29M-$1.41-63.44 Do analysts prefer FTRE or WGS? Fortrea currently has a consensus price target of $15.00, indicating a potential upside of 187.08%. GeneDx has a consensus price target of $90.13, indicating a potential upside of 0.75%. Given Fortrea's higher possible upside, equities research analysts clearly believe Fortrea is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortrea 2 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86GeneDx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is FTRE or WGS more profitable? GeneDx has a net margin of -11.69% compared to Fortrea's net margin of -29.43%. GeneDx's return on equity of 10.17% beat Fortrea's return on equity.Company Net Margins Return on Equity Return on Assets Fortrea-29.43% 2.84% 1.06% GeneDx -11.69%10.17%5.51% Which has more risk and volatility, FTRE or WGS? Fortrea has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Do institutionals & insiders have more ownership in FTRE or WGS? 61.7% of GeneDx shares are owned by institutional investors. 0.4% of Fortrea shares are owned by company insiders. Comparatively, 29.6% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor FTRE or WGS? In the previous week, Fortrea had 16 more articles in the media than GeneDx. MarketBeat recorded 32 mentions for Fortrea and 16 mentions for GeneDx. GeneDx's average media sentiment score of 0.46 beat Fortrea's score of 0.12 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 1 Very Positive mention(s) 1 Positive mention(s) 29 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryGeneDx beats Fortrea on 12 of the 16 factors compared between the two stocks. Get Fortrea News Delivered to You Automatically Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FTRE vs. The Competition Export to ExcelMetricFortreaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$473.04M$2.90B$5.50B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-0.5921.2826.2519.86Price / Sales0.18280.14415.14113.78Price / Cash3.1441.8936.4957.06Price / Book0.347.468.055.38Net Income-$328.50M-$55.05M$3.16B$248.50M7 Day Performance0.87%2.25%1.78%2.78%1 Month Performance26.51%7.17%4.74%5.84%1 Year Performance-78.05%5.13%35.81%20.06% Fortrea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FTREFortrea4.0021 of 5 stars$5.23+0.3%$15.00+187.1%-78.2%$473.04M$2.70B-0.5915,500WGSGeneDx1.8822 of 5 stars$79.71+19.0%$86.75+8.8%+214.7%$1.91B$305.45M-56.531,200Analyst ForecastGap DownHigh Trading VolumeLFSTLifeStance Health Group2.6006 of 5 stars$4.96+2.7%$8.50+71.4%-0.2%$1.88B$1.25B-49.6010,218ARDTArdent Health3.4393 of 5 stars$12.94-0.8%$20.67+59.7%N/A$1.87B$5.97B7.9424,900PGNYProgyny1.7743 of 5 stars$20.79-0.9%$23.45+12.8%-22.3%$1.80B$1.17B36.47310NHCNational HealthCareN/A$106.43+1.5%N/A-1.7%$1.65B$1.37B13.3412,400GRALGRAIL0.6372 of 5 stars$43.07-5.6%$31.50-26.9%N/A$1.64B$125.60M-0.711,360Insider TradeTDOCTeladoc Health3.1716 of 5 stars$7.90+14.5%$9.60+21.5%-8.2%$1.21B$2.57B-1.335,500High Trading VolumeVRDNViridian Therapeutics1.9146 of 5 stars$14.71-0.1%$37.56+155.3%+9.5%$1.20B$300K-3.8250Positive NewsAHCOAdaptHealth3.9233 of 5 stars$8.30-1.1%$13.40+61.4%-3.4%$1.13B$3.26B14.5610,500News CoveragePositive NewsCDNACareDx4.3665 of 5 stars$18.95-0.5%$30.33+60.1%+22.6%$1.06B$333.79M16.48740Positive News Related Companies and Tools Related Companies WGS Competitors LFST Competitors ARDT Competitors PGNY Competitors NHC Competitors GRAL Competitors TDOC Competitors VRDN Competitors AHCO Competitors CDNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FTRE) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortrea Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortrea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
